AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16253066 — intervention group
Group type: COMPARATOR
Intervention: Contour stent
Number of subjects: 44
Study 16253066 — intervention group
Group type: COMPARATOR
Intervention: Endo-Sof stent
Number of subjects: 44
Study 16253066 — intervention group
Group type: COMPARATOR
Intervention: Classic Double-Pigtail stent
Number of subjects: 44
Study 12384075 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted Donati stitches
Number of subjects: 58
Study 12384075 — intervention group
Group type: COMPARATOR
Intervention: Running nylon skin suture
Number of subjects: 58
Study 10443240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tularemia live vaccine (TLV) immunization given 15-20 days before surgery
Number of subjects: 0
Study 10443240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preliminary immunization)
Number of subjects: 0
Study 7756706 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 6 mg/kg
Number of subjects: 11
Study 7756706 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 2 mg/kg
Number of subjects: 11
Study 2312449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHAP)
Number of subjects: 10
Study 2312449 — intervention group
Group type: COMPARATOR
Intervention: Polycose (placebo, P)
Number of subjects: 10
Study 31751790 — intervention group
Group type: EXPERIMENTAL
Intervention: Drained mucosal advancement flap with drainage Seton rerouted around the external anal sphincter
Number of subjects: 97
Study 31751790 — intervention group
Group type: COMPARATOR
Intervention: Rerouting Seton around the internal anal sphincter (IAS)
Number of subjects: 97
Study 29138033 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulator
Number of subjects: 60
Study 29138033 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity simulator (coasterlike model)
Number of subjects: 60
Study 26822630 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 7.5 mg daily for 8 weeks
Number of subjects: 32
Study 26822630 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 32
Study 25160775 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body musculoskeletal disorders among craft workers (ISCO 7), machine operators (ISCO 8), and workers in elementary occupations (ISCO 9)
Number of subjects: 0
Study 25160775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limbs musculoskeletal disorders among service and sales workers (ISCO 5), craft workers (ISCO 7), machine operators (ISCO 8), and workers in elementary occupations (ISCO 9)
Number of subjects: 0
Study 25160775 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical risk factors for both upper body and lower limbs symptoms
Number of subjects: 0
Study 25160775 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing as a risk factor
Number of subjects: 0
Study 22232462 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast with moxidectin (8 mg)
Number of subjects: 54
Study 22232462 — intervention group
Group type: COMPARATOR
Intervention: Fasted subjects with moxidectin (8 mg)
Number of subjects: 54
Study 20951424 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7128 (1000 mg twice daily) and danoprevir (900 mg twice daily)
Number of subjects: 88
Study 20951424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 17949396 — intervention group
Group type: EXPERIMENTAL
Intervention: Murex HIV antigen/antibody combination enzyme immunoassay
Number of subjects: 7333
Study 16117821 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 15
Study 16117821 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone i.v. pulses for 2 weeks followed by oral prednisone for 4 months
Number of subjects: 15
Study 12098632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 51
Study 12098632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10425981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis
Number of subjects: 14
Study 10425981 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution iontophoresis (Control)
Number of subjects: 14
Study 7776110 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of synthetic surfactant
Number of subjects: 826
Study 7776110 — intervention group
Group type: COMPARATOR
Intervention: One dose of synthetic surfactant
Number of subjects: 826
Study 2339974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine (0.6 mg)
Number of subjects: 18
Study 2339974 — intervention group
Group type: COMPARATOR
Intervention: Sea Band (acupressure band)
Number of subjects: 18
Study 2339974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 441422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical application of 0.1, 0.2 or 0.3 mg PG‐E2 in 1 ml viscous gel
Number of subjects: 38
Study 30993400 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + fortified milk
Number of subjects: 180
Study 30993400 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 180
Study 30993400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 180
Study 30993400 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study 31532100 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy pregnant women (experiment group)
Number of subjects: 1194
Study 27339709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based exercises (PE)
Number of subjects: 55
Study 27339709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (CE)
Number of subjects: 55
Study 27339709 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (HE)
Number of subjects: 55
Study 25677713 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-rich snack (containing green leafy vegetables, dried fruit, and whole milk powder)
Number of subjects: 222
Study 25677713 — intervention group
Group type: COMPARATOR
Intervention: Control snack (containing foods of low micronutrient content such as wheat flour, potato, and tapioca)
Number of subjects: 222
Study 24004639 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Circuit Training (HICT)
Number of subjects: 58
Study 24004639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Circuit Training (LICT)
Number of subjects: 58
Study 24004639 — intervention group
Group type: COMPARATOR
Intervention: Endurance Training (ET)
Number of subjects: 58
Study 21272047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole-ER
Number of subjects: 248
Study 21272047 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 248
Study 21272047 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole-DR 20 mg
Number of subjects: 248
Study 19621686 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy
Number of subjects: 87
Study 19621686 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic esophagectomy
Number of subjects: 87
Study 19621686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 87
Study 17259414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral component
Number of subjects: 50
Study 17259414 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite-coated femoral component
Number of subjects: 50
Study 17259414 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating platform design
Number of subjects: 50
Study 17259414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard femoral component
Number of subjects: 50
Study 15134239 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (e.g., warfarin)
Number of subjects: 0
Study 15134239 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-vitamin K drugs (warfarin)
Number of subjects: 0
Study 15134239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (direct anti-thrombin)
Number of subjects: 0
Study 15134239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior anticoagulant treatment before cardioversion
Number of subjects: 0
Study 11345386 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1094
Study 10193278 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lung inflation manoeuvre with 100% oxygen before tracheal extubation (group I; n = 59)
Number of subjects: 120
Study 10193278 — intervention group
Group type: COMPARATOR
Intervention: Suction through the tube during tracheal extubation (group S; n = 61)
Number of subjects: 120
Study 7922426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled, inverse-ratio ventilation
Number of subjects: 0
Study 7922426 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized computerized protocols
Number of subjects: 0
Study 2962712 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% foscarnet cream
Number of subjects: 153
Study 2962712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cream vehicle)
Number of subjects: 153
Study 29943624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment in SHARP eligible patients
Number of subjects: 257
Study 29943624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment in SHARP non-eligible patients
Number of subjects: 257
Study 29943624 — intervention group
Group type: COMPARATOR
Intervention: SHARP ineligibility
Number of subjects: 257
Study 28207951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT, 6-8×5 minutes at halfway between lactate threshold and maximal oxygen uptake [50%Δ])
Number of subjects: 20
Study 28207951 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (CONT, 60-80 minutes at 90% lactate threshold)
Number of subjects: 20
Study 28207951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 20
Study 26480664 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue and metformin hydrochloride
Number of subjects: 27
Study 26480664 — intervention group
Group type: COMPARATOR
Intervention: Insulin and metformin hydrochloride
Number of subjects: 27
Study 23461992 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post‐tetanic count 0‐1)
Number of subjects: 72
Study 23461992 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (at least one response to train‐of‐four nerve stimulation)
Number of subjects: 72
Study 23461992 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 72
Study 21682834 — intervention group
Group type: EXPERIMENTAL
Intervention: Avandamet (rosiglitazone/metformin)
Number of subjects: 688
Study 21682834 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 688
Study 18081360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rouz‐Aciclovir (test)
Number of subjects: 12
Study 18081360 — intervention group
Group type: COMPARATOR
Intervention: Zovirax (reference)
Number of subjects: 12
Study 18081360 — intervention group
Group type: COMPARATOR
Intervention: Rouz‐Aciclovir (test) vs Zovirax (reference)
Number of subjects: 12
Study 17262121 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental ABF (n=4)
Number of subjects: 12
Study 17262121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (n=4)
Number of subjects: 12
Study 17262121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond etch‐and‐rinse adhesive system (n=4)
Number of subjects: 12
Study 17262121 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 15607401 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (90-min treadmill walk)
Number of subjects: 20
Study 15607401 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 20
Study 11333290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (continued therapy)
Number of subjects: 1172
Study 11333290 — intervention group
Group type: COMPARATOR
Intervention: Placebo (discontinued tamoxifen)
Number of subjects: 1172
Study 9204087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 15
Study 9204087 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 15
Study 7704288 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d for 6 weeks)
Number of subjects: 6
Study 7704288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3297214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 14
Study 3297214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30446878 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D genetic risk score (GRS) using 34 T2D risk genetic variants
Number of subjects: 11506
Study 30446878 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D_GRS as the IV
Number of subjects: 11506
Study 30446878 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of the genetic IVs for T2D
Number of subjects: 11506
Study 30446878 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D and depression with IVW after excluding pleiotropic SNPs
Number of subjects: 11506
Study 27719686 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'-O-fucosyllactose (2'FL) and/or lacto-N-neotetraose (LNnT)
Number of subjects: 100
Study 27719686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24115478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) administered chairside during dialysis for 3 months
Number of subjects: 59
Study 24115478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 59
Study 24115478 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 59
Study 23878604 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly yoga classes (n = 49)
Number of subjects: 95
Study 23878604 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly yoga classes (n = 46)
Number of subjects: 95
Study 21159050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) combined with donepezil, 30-minute sessions weekly for 7 weeks.
Number of subjects: 49
Study 21159050 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only donepezil.
Number of subjects: 49
Study 21159050 — intervention group
Group type: EXPERIMENTAL
Intervention: CST group (donepezil + CST)
Number of subjects: 49
Study 21159050 — intervention group
Group type: COMPARATOR
Intervention: Control group (donepezil only)
Number of subjects: 49
Study 18783960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary shunt
Number of subjects: 82
Study 18783960 — intervention group
Group type: COMPARATOR
Intervention: Shuntless group
Number of subjects: 82
Study 16636038 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Cam
Number of subjects: 27
Study 12740229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 0
Study 12740229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 0
Study 12740229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 0
Study 10340371 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 10340371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 7727669 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and injectable meglumine antimonate (20 mg of antimony [Sb]/kg.d) for 10 days and 7 days respectively
Number of subjects: 39
Study 7727669 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and injectable meglumine antimonate (20 mg of antimony [Sb]/kg.d) for 10 days and 3 days respectively
Number of subjects: 39
Study 7727669 — intervention group
Group type: COMPARATOR
Intervention: Injectable meglumine antimonate (Sb) alone for 10-15 days (historical controls)
Number of subjects: 39
Study 2523657 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 to 7.5 mg twice daily)
Number of subjects: 23
Study 127945 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous procaine penicillin G, 4.8 million units intramuscularly plus 1 g of oral probenecid
Number of subjects: 9008
Study 127945 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-probenecid
Number of subjects: 9008
Study 127945 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 9008
Study 127945 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 9008
Study 30395314 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 0
Study 30395314 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 30858230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-trigger group (hemoglobin < 8.0 g/dL)
Number of subjects: 58
Study 30858230 — intervention group
Group type: COMPARATOR
Intervention: High-trigger group (hemoglobin < 9.7 g/dL)
Number of subjects: 58
Study 28698268 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV+VG
Number of subjects: 42
Study 28698268 — intervention group
Group type: COMPARATOR
Intervention: SIMV+VG
Number of subjects: 42
Study 25867874 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion 0.02 mg/kg/h after 0.1 mg/kg iv bolus
Number of subjects: 60
Study 25867874 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion 0.25 µg/kg/min following 1 µg/kg iv bolus
Number of subjects: 60
Study 25867874 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion 0.50 µg/kg/min following 10 µg/kg iv bolus
Number of subjects: 60
Study 25867874 — intervention group
Group type: COMPARATOR
Intervention: Saline 5 cc iv bolus and 10 cc/h infusion for induction and maintenance
Number of subjects: 60
Study 23777510 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month period of auto-titrating CPAP
Number of subjects: 0
Study 23777510 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22389988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine
Number of subjects: 75
Study 22389988 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 75
Study 19018449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 16
Study 19018449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17485570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/metformin 2,000 mg (S100/M2000)
Number of subjects: 1091
Study 17485570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/metformin 1,000 mg (S100/M1000)
Number of subjects: 1091
Study 17485570 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2,000 mg (M2000)
Number of subjects: 1091
Study 17485570 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1,000 mg (M1000)
Number of subjects: 1091
Study 17485570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg (S100)
Number of subjects: 1091
Study 17485570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/metformin 2,000 mg (S100/M2000) in open-label cohort
Number of subjects: 1091
Study 17485570 — intervention group
Group type: COMPARATOR
Intervention: All active treatment groups
Number of subjects: 1091
Study 17485570 — intervention group
Group type: COMPARATOR
Intervention: Co-administration therapies vs respective metformin monotherapy
Number of subjects: 1091
Study 15447957 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal perfusion without compensation for respiratory misregistration
Number of subjects: 43
Study 15447957 — intervention group
Group type: COMPARATOR
Intervention: Portal perfusion with compensation for respiratory misregistration
Number of subjects: 43
Study 15447957 — intervention group
Group type: COMPARATOR
Intervention: Patients with chronic hepatitis
Number of subjects: 43
Study 15447957 — intervention group
Group type: COMPARATOR
Intervention: Patients with liver cirrhosis
Number of subjects: 43
Study 15447957 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal liver
Number of subjects: 43
Study 15447957 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal perfusion in liver tumour patients
Number of subjects: 43
Study 11243908 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenter head size 300mm² at 0.25 Hz
Number of subjects: 36
Study 11243908 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenter head size 720mm² at 0.5 Hz
Number of subjects: 36
Study 11243908 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenter head size 1564mm² at 2 Hz
Number of subjects: 36
Study 11243908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast testing frequency (2 Hz)
Number of subjects: 36
Study 11243908 — intervention group
Group type: EXPERIMENTAL
Intervention: Small indenter heads at slow speed (0.25 Hz)
Number of subjects: 36
Study 9526964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 30 mg/day
Number of subjects: 12
Study 9526964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day
Number of subjects: 12
Study 9526964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7993330 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (stimulus control, urge control, contracting/family support, competing response procedures) for an average of 19 sessions
Number of subjects: 82
Study 7993330 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment (alternative treatment)
Number of subjects: 82
Study 7993330 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 82
Study 2951426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary dosage of ipratropium (80 micrograms four times a day)
Number of subjects: 36
Study 2951426 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy of ipratropium (400 micrograms four times a day)
Number of subjects: 36
Study 2951426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29311299 — intervention group
Group type: EXPERIMENTAL
Intervention: Group malleability intervention
Number of subjects: 508